OSSIO Closes Series C Financing of $38.5 Million
Summary
WOBURN, Mass.--(BUSINESS WIRE)--OSSIO, Ltd., a fast-growing orthopedic fixation technology company, announced today that it has closed $38.5 million in Series C financing. Along with the participation of current shareholders, the round was led by MVM Partners, a Boston- and London-based growth equity firm investing in innovative, commercial stage healthcare companies that address high unmet medical needs.We are delighted to have secured this level of interest and commitment from such an experienced and distinguished medical technology investment firm, said OSSIOs chief executive officer, Brian Verrier. Founded in 2014, its vision is to provide the first credible replacement to metal implants in the multibillion-dollar global orthopedic fixation market with its OSSIOfiber Intelligent Bone Regeneration Technology. For more information on the company, visit www.ossio.io.Forward-looking statements contained herein are based on estimates and assumptions of OSSIO management and are believed to be reasonable, though they are inherently uncertain and difficult to predict.MVM has invested in high growth healthcare businesses since 1997. The firm has a broad, global investment outlook spanning medical technology, pharmaceuticals, diagnostics, digital health, and other sectors of healthcare.